Abstract 98P
Background
Advances in next-generation sequencing (NGS) make possible the selection of highly targeted therapies based on a tumour's genetic profile, resulting in better outcomes with a potential impact on progression-free survival and overall survival (Bewicke-Copley F, 2019; Gibbs SN, 2023; Coquerelle S, 2020). Moreover, it seems to be a cost-effective test (Pruneri G, 2021). ESMO Scale of Actionability of molecular Targets (ESCAT) aids in evaluating treatment efficacy, emphasizing the promise of personalized medicine in cancer care (Mateo J, 2018; Mosele F, 2020; Mosele F, 2024). Therefore, we decided to review the experience of the test in our center together with the ESCAT.
Methods
A retrospective observational study was carried out with cancer patients who had undergone a NGS test from January 2017 to December 2023 in the Medical Oncology Service of our hospital. The study has been approved by the Ethics Committee.
Results
96 patients with a mean age of 54 years were included, 56% of whom were women. The most frequent tumours were cholangiocarcinoma (24%), colorectal cancer (16%), lung cancer (12%) and cancer of unknown primary (6%). 56% of the samples come from tissue and 100% of them were valid for examination. In 23% of cases the test was requested in the first-line setting. The mean number of tumor mutational burden and genomic alterations found was 5 respectively. The MAPK and cell-replication were the most frequently altered signalling pathways and 3% had microsatellite instability. An average of 16 clinical trials were available for these patients. 22% had actionable mutations with targeted therapy and tumor-specific evidence and 24% exhibited mutations but with evidence-based treatments for other tumour types. 34% of patients received treatment based on NGS results after the test, while 8% received it but in later treatment lines. 49% had a favourable ESCAT classification (I-II).
Conclusions
In our clinical experience the NGS test should be implemented in routine clinical practice for decision making. In order to benefit from the test, patients should be selected according to ESMO guidelines. ESCAT is a useful instrument to exploit. Prospective studies should be performed with a more homogeneous population to assess the impact of the NGS test and the ESCAT.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
82P - Applying computational approaches to build a predictive protein structure and discover novel inhibitors for mitotic serine/threonine kinase BUB1B
Presenter: Joan Glenny Pescov
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Development of a cell-free DNA scoring system from organoid culture medium to predict drug response in bladder cancer
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Quinacrine inhibits angiogenesis and migration of non-small cells lung cancer cells (NSCLC) by binding with the kinase domain of VEGFR2
Presenter: Angshuman Sarkar
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - HDAC6-mediated regulation of progesterone receptor: Implications for hormonal therapy in breast cancer
Presenter: Wafaa Ramadan
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Functional impact of miR-205-5p on cervical cancer cell behavior and chemotherapy response
Presenter: Rhafaela Causin
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Impact of poly(ADP-ribose) polymerase (PARP) mutations on interaction with PARP inhibitors (iPARPs)
Presenter: JUAN DIAZ ACOSTA
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma in multicellular spheroid model
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Clinical phenotyping of lung cancer-associated cachexia in relation to tumour volume in TRACERx
Presenter: Kexin Koh
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Are patients with measurable residual disease (MRD) positive or MRD negative different in baseline DNA methylation signatures in precursor B-cell acute lymphoblastic leukaemia (B-ALL)?
Presenter: Ramya Ramesh
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Prognostic value of tumor location and site-specific metastases in advanced biliary tract cancer
Presenter: Vanessa Patel
Session: Cocktail & Poster Display session
Resources:
Abstract